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Aims: Biliary atresia (BA) is thought to be associated with infections by viruses such as Reoviridae 
and is characterized histologically by fibrosclerosing cholangitis with proinflammatory 
cytokine-mediated inflammation. IL-32 affects the continuous inflammation by increasing the 
production of proinflammatory cytokines. In this study, the role of IL-32 in the cholangitis of BA 
was examined. Methods: Immunohistochemistry for IL-32 and caspase 1 was performed using 21 
samples of extrahepatic bile ducts resected from BA patients. Moreover, using cultured human 
biliary epithelial cells (BECs), the expression of IL-32 and its induction on stimulation with a 
Toll-like receptor (TLR) 3 ligand (poly(I:C)) and proinflammatory cytokines was examined. 
Results: BECs composing extrahepatic bile ducts showing cholangitis expressed IL-32 in BA, but 
not in controls. Caspase 1 was constantly expressed on BECs of both BA and control subjects. 
Furthermore, poly(I:C) and proinflammatory cytokines (IL-1β, IFN-γ, and TNF-α) strongly induced 
IL-32 expression in cultured BECs, accompanying the constant expression of TLR3 and caspase 1. 
Conclusions: Our results imply that the expression of IL-32 in BECs was found in the damaged bile 
ducts of BA and induced by biliary innate immunity via TLR3 and proinflammatory cytokines. 
These findings suggest that IL-32 is initially involved in the pathogenic mechanisms of cholangitis 
in BA and also plays an important role in the amplification and continuance of periductal 
inflammatory reactions. It is therefore tempting to speculate that inhibitors of IL-32 could be useful 
for attenuating cholangitis in BA. 


































































The obliterative lesion of biliary atresia (BA) is characterized by a progressive sclerosing 
cholangitis accompanying severe inflammation, fibrosis, and epithelial injuries and this 
characteristic feature is known as fibrosclerosing cholangitis. Little is known about the etiology and 
pathogenesis of BA, but infections by viruses such as Reoviridae (reovirus and rotavirus) having a 
double-stranded RNA (dsRNA) have been implicated, though conflicting results also have been 
reported [1-8]. Our recent study has demonstrated that biliary epithelial cells (BECs) possess an 
innate immune system consisting of Toll-like receptors (TLR), especially TLR3 which is an innate 
immune-recognition receptor recognizing dsRNA including dsRNA viruses as pathogen-associated 
molecular patterns (PAMPs) [9, 10]. Furthermore, the biliary innate immune response to artificial 
dsRNA was also shown to be associated with the induction of biliary apoptosis via the tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) and, differing from the innate immune 
response to TLR4 ligand (LPS), lack of subsequent tolerance to dsRNA using cultured human biliary 
epithelial cells [9-11]. 
 Interleukin (IL)-32 is a recently described cytokine produced by T lymphocytes, natural 
killer (NK) cells, monocytes and some epithelial cells [12, 13]. Primarily, IL-32 was discovered in 
the synovial fluid of patients with rheumatoid arthritis and first reported as a transcript in IL-2 
activated NK and T cells [14, 15]. There are six isoforms (α, β, γ, δ, ε, and ξ) caused by alternative 
mRNA splicing, resulting in proteins with a molecular weight ranging from 14.9 to 26.7 kD. IL-32α 
is the most abundant transcript. IL-32 exhibits several properties typical of proinflammatory 
cytokines [16]. For example, it stimulates the secretion of proinflammatory cytokines and 
chemokines such as IL-1α, TNF-α, IL-6, IL-8 and VEGF through the activation of nuclear factor-κB 
(NF-κB) and p38 mitogen-activated protein kinases (MAPKs) [15, 17, 18]. In contrast, the 
production of IL-32 is induced or enhanced by the presence of proinflammatory cytokines including 
IL-1β, IFN-γ, and TNF-α via the activation of caspase 1 [17, 19, 20]. IL-32 has been implicated in 
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inflammatory disorders such as rheumatoid arthritis, inflammatory bowel diseases, chronic 
obstructive pulmonary diseases, atopic dermatitis, and allergic rhinitis [14, 19-22].  
 Although human hepatocytes and hepatoma cells express IL-32 in HCV-associated chronic 
hepatitis and the expression is regulated by proinflammatory stimuli [23], the pathophysiological 
role of IL-32 in innate immune-related biliary diseases including BA remains unclear. We therefore 
investigated the IL-32 expression in the inflamed bile ducts of BA patients and the effect of innate 
immune stimulation by ligands of TLR3 and cytokines on IL-32 expression in cultured human BECs. 
Our results provide evidence that biliary epithelial cells are sufficient sources of IL-32 for the biliary 
inflammation at sites of BA and IL-32 may therefore play a role in the pathophysiology of BA. 
 
 
MATERIALS AND METHODS 
 
Patients and tissue preparations 
 A total of 21 patients with BA (surgical specimens; average age 1.7 months; range of age 
0.7-12 months; male/female=9/12) and age-matched control patients consisting of one neonatal 
hepatitis (giant cell hepatitis; wedge biopsy; 3 months; male) and 6 non-hepatobiliary diseases 
(congenital heart anomalies; autopsied specimens; average age 2.5 months; male/female=3/3) were 
examined. Resected common bile ducts and wedge liver biopsy specimens obtained at Kasai 
procedure from the patients with BA were used. These specimens had been fixed in 10% 
neutral-buffered formalin and embedded in paraffin; 4µm-thick sections were prepared for histologic 
observation and immunohistochemistry.  
Immunohistochemistry and immunocytochemistry 
For the immunocytochemistry using cultured BECs, formalin-fixed, paraffin-embedded 
sections of cell blocks were prepared according to the protocol reported by Mayall, et al [24]. The 
deparaffinized and rehydrated sections were heated in 10mM citrate buffer for 20min in a 
microwave oven. Following the blocking of endogenous peroxidase, these sections were incubated at 
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4ºC overnight with antibody against the C-terminus of IL-32 (rabbit polyclonal IgG, 1µg/ml, 
Lifespan, Seattle, WA, USA), TLR3 (rabbit polyclonal IgG, 1µg/ml, Santa Cruz, Santa Cruz, CA, 
USA), and caspase 1 (rabbit monoclonal IgG, diluted 1:1,000, Abcam, Tokyo, Japan) and then at 
room temperature for 1h with anti-rabbit immunoglobulins conjugated to a peroxidase-labeled 
dextran polymer (Simple staining kit, Nichirei, Tokyo, Japan). After a benzidine reaction, sections 
were lightly counterstained with hematoxylin. As a negative control, normal rabbit IgG was used as 
the primary antibody: no staining was obtained.  
For the semi-quantitative evaluation of the immunohistochemistry, intrahepatic bile ducts 
and extrahepatic common bile ducts were chosen in each section for assessment and IL-32 
immunoreactivity in these bile ducts was semiquantitatively graded as follows: score 0, absence of 
expression; score 1, low constitutive expression; score 2, intermediate expression; score 3, high 
expression.  
 In addition, simultaneous detection of IL-32 and cytokeratin (CK)19 was done using 
double immunohistochemical staining. After IL-32 immunostaining, CK19 antibody (mouse 
monoclonal IgG1kappa, 0.45µg/ml, Dako Japan, Tokyo, Japan) was applied overnight at 4oC, 
followed by immunoglobulins conjugated to alkaline phosphatase labeled-dextran polymer 
(Nichirei). Color development of IL-32 and CK19 was achieved with diaminobenzidine (brown) and 
Vector blue (Vector Lab, Burlingame, CA, USA.), respectively.   
 
Cultured human BECs and stimulation with PAMPs and proinflammatory cytokines 
 A cultured cell line of human intrahepatic BECs was established from the explant liver of a 
24-year-old male with BA who had already received Kasai procedure during the newborn period, 
and cultured as previously reported [25] The cultured BECs were incubated with a culture medium 
composed of D-MEM/F-12 (Invitrogen, Tokyo, Japan), 5% newborn calf serum (Invitrogen), 
0.18mM adenine (Sigma, Saint Louis, MO, USA), hydrocortisone (0.4µg/ml), cholera toxin 
(10ng/ml), tri-iodo-thyronine (1.3µg/l), ITS+ (Becton Dickinson, Franklin Lakes, NJ, USA), 25mM 
sodium bicarbonate (Sigma), 1% antibiotics antimycotic, human epidermal growth factor(20ng/ml) 
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(Invitrogen), and human hepatocyte growth factor(10ng/ml) (Invitrogen). The cells were grown as 
monolayers in a humidified incubator with 5% CO2 at 37
o
C. More than 95% of the cells were 
confirmed to be biliary epithelial cells by the expression of a biliary-type cytokeratin (CK19). The 
cultured BECs were used between passages 4 and 9. Informed consent for human research was 
obtained from the patient prior to surgery. This study was approved by the Kanazawa University 
Ethics Committee. Moreover, as control cultured cells, a commercially available cell line derived 
from human hepatocellular carcinoma, HepG2, was obtained from Health Science Research 
Resources Bank (Osaka, Japan).  
These cultured cells were stimulated with a TLR3 ligand, polyinosinic-polycytidylic acid 
(poly(I:C), a synthetic analogue of viral dsRNA, 25µg/ml, Invivogen, San Diego, CA, USA) and 
recombinant cytokines (IL-1β, IFN-γ, TNF-α, TGF-β1, and IL-10, l,000U/ml, PeproTech, London, 
and IL-32, 1,000U/ml, R&D system, Minneapolis, MN, USA) for 3 hrs (molecular analysis) and 48 
hrs (protein analysis by immunocytochemistry and Western blotting analysis). 
 
Isolation of RNA, reverse transcription-polymerase chain reaction (RT-PCR), and real-time PCR  
 For the evaluation of mRNA of IL-32, caspase 1, TLR3, IL-1β, and IL-6, in cultured BECs, 
isolation of RNA from BECs and reverse transcription were performed using the RNeasy Total RNA 
System (Qiagen, Hilden, Germany) and ReverTra Ace (Toyobo, Osaka, Japan). First, to examine the 
presence of target molecules and the validity of the newly designed primers, conventional PCR was 
performed. Specific primers for IL-32, caspase 1, TLR3, and glyceraldehyde 3 phosphate 
dehydrogenase (GAPDH, positive control) were designed: IL-32 forward, 
5’-AGCTGGAGGACGACTTCAAA-3’, and reverse, 5’-TTGAGGATTGGGGTTCAGAG-3’ 
(predicted size, 258bp); TLR3 forward, 5’-CCATTCCAGCCTCTTCGTAA-3’, and reverse, 
5’-GGATGTTGGTATGGGTCTCG-3’ (predicted size, 505bp); caspase 1 forward, 
5’-CCACAATGGGCTCTGTTTTT-3’, and reverse, 5’-CATCTGGCTGCTCAAATGAA-3’ 
(predicted size, 117); IL-1β, forward, 5'-CCAGGGACAGGATATGGAGCA-3' and reverse, 
5'-TTCAACACGCAGGACAGGTACAG-3' (predicted size, 129bp); IL-6, forward, 
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5'-AGTGAGGAACAAGCCAGAGC-3' and reverse, 5'-AAGCTGCGCAGAATGAGAT-3' 
(predicted size, 189bp); GAPDH, forward, 5’-GGCCTCCAAGGAGTAAGACC-3’, and reverse, 
5’-AGGGGTCTACATGGCAACTG-3’ (predicted size, 147bp). The reaction profile consisted of 
initial denaturation at 94ºC for 3min followed by 25-40 cycles with 30sec of denaturation at 94ºC, 
30sec of annealing of primers at 55ºC, and a 60sec extension at 72ºC. Next, to carry out relative 
quantification, real-time quantitative PCR was performed according to a standard protocol using the 
Brilliant II SYBR Green QPCR Reagents and Mx300P QPCR system (Stratagene Japan, Tokyo, 
Japan). Relative gene expression was calculated using the comparative cycle threshold method and 
adjusted based on the expression of house-keeping gene (GAPDH). Results were obtained from 
three independent experiments and shown as relative mRNA expression compared with the level 
without any treatments. Negative controls were obtained by replacing the reverse transcriptase or 
cDNA samples with RNase and DNase free water. 
 
Western blotting 
Cell lysates of poly(I:C)-stimulated or unstimulated cultured cell lines (10µg protein/lane) and 
the culture medium were subjected to SDS-PAGE. Recombinant IL32 protein (0.1µg, R&D) was 
used as a positive control. Separated proteins were transferred to a nitrocellulose membrane; the 
membrane was blocked in 5% bovine serum albumin, and then probed for 1h with a primary antibody 
against human IL-32 (0.1µg/ml). After a wash, the membrane was incubated for 1h with a Simple 
Staining Kit, and visualized with the benzidine reaction. The density of bands was quantitatively 
evaluated by using NIH images. 
 
Statistical analysis 
 Data were analyzed using the paired t-test or Welch’s t-test; p<0.05 was considered 
statistically significant.  
 
 


































































Expression of IL-32, caspase 1, and TLR3 in extrahepatic bile ducts of BA 
Immunohistochemistry revealed the expression of IL-32 in BECs, infiltrating inflammatory 
cells, and endothelial cells at various intensities. In particular, damaged common bile ducts showing 
cholangitis in BA strongly expressed IL-32, accompanying many IL-32-positive inflammatory cells 
and vessels (Fig.1A, 1B, 1C). As shown in Fig.1F, the double immunohistochemistry highlighted 
that CK19-postive bile ducts clearly expressed IL-32. However, non-damaged biliary epithelium 
found at the margin of resected common bile ducts did not express IL-32 (Fig.1G and 1H). In wedge 
liver biopsies, hepatocytes were also positive for IL-32 in addition to small bile ducts (interlobular 
bile ducts), but the intensity was lower than that in damaged common bile ducts (Fig.1I and 1J). 
Moreover, congestive bile in intrahepatic bile ducts was also strongly positive for IL-32 (Fig.1J). In 
contrast, BECs in common bile ducts and intrahepatic bile ducts of age-matched controls, only 
weakly expressed or lacked IL-32 (Fig2A and 2D). The semi-quantitative analysis for 
immunoreaction confirmed the expression of IL-32 in damaged common bile ducts of BA was 
significantly upregulated, compared with those in non-damaged/normal bile ducts of BA and 
age-matched controls (Fig.3). Caspase 1 and TLR3 were constantly expressed in BECs of 
extrahepatic bile ducts, in both the BA and control patients (Fig.2B and 2C).  
 
Induction of IL-32 expression by PAMPs and cytokines in cultured BECs 
To examine the presence of target molecules and the validity of the newly designed primers, 
RT-PCR at 40 cycles was performed and an amplification of all molecules could be detected as a 
single band from cultured BECs at the expected size. Moreover, the BECs constantly expressed the 
mRNA of TLR3 and caspase 1, which is necessary for the recognition of poly(I:C) and the 
production of functional IL-32 protein, respectively. The real-time PCR analysis revealed that TLR3 
ligand, poly(I:C) and proinflammatory cytokines (IL-1β, IFN-γ, and TNF-α), but not regulatory 
cytokines (TGF-β1 and IL-10), enhanced the mRNA expression of IL-32, with the increases being 
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statistically significant (Fig.4A). In contrast, the stimulation with IL-32 did not significantly 
upregulated the expression of BEC-producing cytokines (IL-1β, IL-6, and IL-32), TLR3, and 
caspase 1 in cultured BECs (Fig.4B). Although the control cell line, HepG2, also expressed IL-32 
mRNA, the upregulation of IL-32 was not significant by the stimulation with poly(I:C) or IL-32 
(Fig.4C).  
 
Detection of intracytoplasmic and secreted IL-32protein 
 To investigate the secretion of the IL-32 protein, Western blotting was performed using the 
cell lysate and culture medium of BECs. IL-32 was detected in the medium as well as lysate from 
the poly(I:C)-stimulated BECs (Fig.5A). Semi-quantitative analysis using NIH image analysis 
revealed that the density of bands was upregulated in cell lysate and culture medium by the 
stimulation with poly(I:C) (Fig.5A). Moreover, immunocytochemistry also demonstrated that IL-32 







 BA is initially characterized by periductal inflammation and fibrosis, and the obstruction 
of common bile ducts, known as fibrosclerosing cholangitis. Recruitment of inflammatory cells 
results in the release of other proinflammatory cytokines and chemokines, sustaining the cholangitis 
associated with the biliary innate immune response and promoting the chronic cholangitis associated 
with the subsequent acquired immune response in a later phase [26]. IL-32 is a recently described 
cytokine that is a strong inducer of pro-inflammatory cytokines and whose expression is markedly 
increased in several inflammatory disorders including RA and IBD and correlated with the severity 
of these diseases [14, 19]. In the present study, human BECs were demonstrated to be the local 
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source of IL-32. Immunohistochemical analysis showed a cytoplasmic distribution of IL-32 in BECs 
of the damaged common bile ducts in the cases of BA, though BECs of common bile ducts in 
age-matched controls were negative or only weakly positive for IL-32, suggesting that IL-32 is 
closely associated with the histogenesis of periductal inflammation in BA. However, the event of 
IL-32 production in BECs is not be specific for only BA. In facts, we confirmed the expression of 
IL-32 in bile ducts of adult biliary diseases such as primary biliary cirrhosis, but its intensity was 
lower than those in the damaged common bile ducts of BA. Therefore, we speculated that the 
induction of IL-32 by unique factors such as viral infections in BA was stronger than those in other 
biliary diseases. Inflammasomes are multi-protein cytoplasmic complexes that mediate the activation 
of inflammatory caspase-1. For example, caspase-1 cleaves pro-IL-1β to the active form IL-1β. In 
this manner, caspase-1 controls the maturation of some of the pro-inflammatory cytokines and IL-32 
also depended on the activation of caspase 1 [17, 20]. Therefore, the presence of caspase 1 is 
necessary for the functional expression of IL-32 in BECs. In the present study, BECs constantly 
expressed caspase 1 in vitro and in vivo, suggesting the expression of a functional IL-32 in BECs.  
 Recent studies have focused on the role of innate immunity associated with Reoviridae 
(reovirus and rotavirus) in the pathogenesis of BA. Reoviridae having a dsRNA genome, in 
particular, are characterized by epithelial tropism [1, 3, 4, 9, 10, 27, 28]. The initial sensing of innate 
immunity is mediated by the recognition of PAMPs through TLRs. IL-32 also appears to play an 
important role in host defense against invading micro-organisms [23, 29, 30]. That is, IL-32 is 
described as a pro-inflammatory cytokine that enhances host immunity against various microbial 
pathogens. The present study revealed that stimulation with poly(I:C), a mimic of Reoviridae, 
enhanced the expression of IL-32 in cultured BECs, suggesting that the biliary innate immune 
response directly induces the production of IL-32 in BECs. A control cell line used in this study, 
HepG2, also expressed IL-32 mRNA, but the upregulation of IL-32 was not significant by the 
stimulation with poly(I:C). It has already been reported that IL-32 expression is induced in 
peripheral blood mononuclear cells and monocytes by Mycobacterium tuberculosis [31], but to our 
knowledge this is the first description concerning the production of IL-32 in epithelial cells such as 
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BECs via an innate immune response.  
 IL-1β, IFN-γ, and TNF-α were reported to be inducers of IL-32 expression [16, 19]. 
However, the regulatory mechanism of these pro-inflammatory cytokines remains unclear. In this 
study, we found that all these pro-inflammatory cytokines are potent stimulators of IL-32 expression 
in cultured BECs. In contrast, the aforementioned results suggest that the secretion of IL-32 could 
stimulate periductal inflammatory and/or immune cells to secrete proinflammatory cytokines and 
contributes to the deterioration of periductal inflammation. Because these inflammatory cytokines 
and an innate immunity play important roles in the immune-mediated histogenesis of BA, the 
inflammatory responses and innate immune response in the affected bile ducts of BA patients may 
be amplified by constant IL-32-induced secretion of proinflammatory cytokines from BECs and 
periductal inflammatory cells, suggesting that IL-32 plays a central role in the inflammatory 
responses involved in the pathogenesis of BA. However, IL-32 itself could not upregulate the 
expression of inflammatory cytokines (IL-1β, IL-6, and IL-32), TLR3, and caspase 1 in cultured 
BECs, suggesting that IL-32 produced by BECs was unlikely involved in direct reciprocal signaling 
resulting in upregulation of inflammatory cytokines and of susceptibility to virus in BECs. 
 In this study, we demonstrated that stimulation with poly(I:C) induced the transcription of 
IL-32 mRNA in BECs and also confirmed the presence of the protein in the culture medium as well 
as cell lysate. Moreover, immunohistochemistry also revealed that a condensed bile in intrahepatic 
small bile ducts was positive for IL-32. These findings suggest the secretion of IL-32 from 
IL-32-expressing BECs. Therefore, IL-32 is speculated to be extracellularly secreted in periductal 
tissue fluids and into bile in BA. As mentioned above, the secreted IL-32 induces the production of 
proinflammatory cytokines in inflammatory and/or immune cells, resulting in a marked 
amplification of inflammatory cytokine milieu, and these responses may contribute to the 
aggravation of BA. Moreover, it was recently suggested that IL-32 acts as a cytoplasmic protein: 
IL-32 was expressed at high levels in human epidermal keratinocytes after stimulation with IFN-γ 
and TNF-α, but was not secreted by keratinocytes [21]. Moreover, it was also shown that the 
upregulation of cytoplasmic IL-32 expression induces apoptosis [21, 32]. In IBD, the apoptosis of 
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damaged colonic cells by accumulated intracellular IL-32 can be considered a host defense 
mechanism against invading microorganisms, by which damaged epithelial cells are eliminated 
efficiently along with invading microorganisms and further invasions of microorganisms can be 
blocked [19, 33]. In BA, our previous study found that biliary apoptosis was enhanced in the 
damaged common bile ducts and closely associated with bile duct loss in BA, which was caused by 
the production of an apoptosis-inducer, TRAIL, in BECs via the biliary innate immune response to a 
TLR3 ligand, poly(I:C) [10]. However, this TRAIL-mediated biliary apoptosis is only partially 
involved in the poly(I:C)-induced mechanism and other possible mechanisms also could exist [10]. 
Therefore, the IL-32-mediated mechanism is also likely in the poly(I:C)-induced biliary apoptosis 
and might be associated with the enhanced biliary apoptosis in the damaged common bile ducts of 
BA. 
 In conclusion, we have demonstrated that IL-32 expression is enhanced in the damaged 
common bile ducts of BA patients. Expression of IL-32 in BECs was induced by the innate immune 
response to dsRNA (poly(I:C)) and proinflammatory cytokines (IL-1β, IFN-γ, and TNF-α). This 
study identified IL-32 as an important inflammatory cytokine involved in the cholangitis of BA. So 
far, anti-IL32 treatment has been studied in a few diseas s such as rheumatoid arthritis [34, 35]. The 
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Fig.1  Histology and immunohistochemistry for IL-32, TLR3, and caspase 1 in biliary atresia (BA). 
A and B: Transverse sections of biliary remnants. Damaged extrahepatic bile ducts 
inconsistently line by desquamated columnar epithelium and surrounding fibroplasia with an 
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inflammatory cell infiltrate. B is a higher magnification of A. H&E staining. Original 
magnification, A, x100 and B, x400. C, D, and E: Immunohistochemistry for IL-32 (C), TLR3 
(D), and caspase 1 (E). The strong expression of IL-32, TLR3, and caspase 1 was found in 
biliary epithelial cells (arrows) of damage bile ducts. Original magnification, x400. F: Double 
immunohistochemistry for CK19 and IL-32 highlighted the CK19-postive bile ducts (blue) 
clearly expressed IL-32 (brown) (arrows). Original magnification, x400. G and H: 
Immunohistochemistry for IL-32. Undamaged extrahepatic bile duct located at the resected 
margin in BA. IL-32-positive neovascular structures (arrowhead) were found, but undamaged 
biliary epithelium lacked IL-32 expression (arrows). H is higher magnification of G. Original 
magnification, G, x200 and H, x400. I and J: Immunohistochemistry for IL-32 using wedge 
liver specimens of BA. Interlobular bile ducts (arrows in I) and hepatocytes (HC in I) 
expressed IL-32. Moreover, condensed bile in dilated bile ducts was also strongly positive for 
IL-32 (arrows in J). J is a higher magnification of I. Original magnification, E, x200 and F, 
x400.  


































































Fig.2  Immunohistochemistry for IL-32 (A and D), TLR3 (B), and caspase 1 (C) in age-matched 
controls. A, B, and C: Biliary epithelial cells in common bile ducts of non-hepatobiliary 
diseases (congenital heart anomalies) expressed TLR3 (B) and caspase 1 (C), but lack or 
faintly expressed IL-32 (A). was faint or negative. Original magnification, x200. D: 
Interlobular bile duct in neonatal hepatitis was negative for IL-32 (arrow). Original 
magnification, x400. 


































































Fig.3  Semi-quantitative analysis of immunohistochemistry for IL-32. The expression of IL-32 in 
damaged common bile ducts (CBD) of biliary atresia (BA) was significantly upregulated, 
compared with those of non-damaged CBD and interlobular bile ducts (ILBD) in BA, and of 
CBD and ILBD in age-matched controls. *<0.05. 



































































Fig.4 A: Induction of IL-32 expression by TLR3 ligand (poly I:C) and cytokines in cultured biliary 
epithelial cells (BECs). Quantitative analysis using real-time PCR revealed that a TLR3 
ligand, poly(I:C), and proinflammatory cytokines (IL-1β, IFN-γ, and TNF-α), but not 
regulatory cytokines (TGF-β1 and IL-10), significantly upregulated the mRNA expression of 
IL-32. B: Detection of BEC-producing cytokines (IL-1β, IL-6, and IL-32), TLR3, and caspase 
1 in cultured BECs. The stimulation with IL-32 did not significantly upregulated the 
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expression of any cytokines, TLR3, or caspase 1. C: Detection of IL-32 in a control cell line, 
HepG2. Induction of IL-32 expression was not found by the stimulation with poly(I:C) or 
IL-32. Results were obtained from three independent experiments and shown as relative 
mRNA expression compared with the level without any treatments (Non). Bars indicate the 
mean±S.E.M. *<0.05. 


































































Fig.5 Detection of intracytoplasmic and secreted IL-32 protein in cultured biliary epithelial cells 
(BECs). A: Western blotting revealed that the culture medium as well as cell lysate of 
poly(I:C)-treated cultured cells contained IL-32 protein, but the level was faint in untreated 
cells (Non). As a positive control, recombinant IL-32 (rIL32, 0.1µg) was used. 
Semi-quantitative analysis using NIH image analysis confirmed that the density of bands was 
upregulated in cell lysate and culture medium by the stimulation with poly(I:C). B: 
Immunocytochemistry also demonstrated that IL-32 was strongly expressed in the 
poly(I:C)-stimulated BECs, compared with the unstimulated BECs (Non). Original 
magnification, x400. 
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Aims: Biliary atresia (BA) is thought to be associated with infections by viruses such as Reoviridae 
and is characterized histologically by fibrosclerosing cholangitis with proinflammatory 
cytokine-mediated inflammation. IL-32 affects the continuous inflammation by increasing the 
production of proinflammatory cytokines. In this study, the role of IL-32 in the cholangitis of BA 
was examined. Methods: Immunohistochemistry for IL-32 and caspase 1 was performed using 21 
samples of extrahepatic bile ducts resected from BA patients. Moreover, using cultured human 
biliary epithelial cells (BECs), the expression of IL-32 and its induction on stimulation with a 
Toll-like receptor (TLR) 3 ligand (poly(I:C)) and proinflammatory cytokines was examined. 
Results: BECs composing extrahepatic bile ducts showing cholangitis expressed IL-32 in BA, but 
not in controls. Caspase 1 was constantly expressed on BECs of both BA and control subjects. 
Furthermore, poly(I:C) and proinflammatory cytokines (IL-1β, IFN-γ, and TNF-α) strongly induced 
IL-32 expression in cultured BECs, accompanying the constant expression of TLR3 and caspase 1. 
Conclusions: Our results imply that the expression of IL-32 in BECs was found in the damaged bile 
ducts of BA and induced by biliary innate immunity via TLR3 and proinflammatory cytokines. 
These findings suggest that IL-32 is initially involved in the pathogenic mechanisms of cholangitis 
in BA and also plays an important role in the amplification and continuance of periductal 
inflammatory reactions. It is therefore tempting to speculate that inhibitors of IL-32 could be useful 
for attenuating cholangitis in BA. 


































































The obliterative lesion of biliary atresia (BA) is characterized by a progressive sclerosing 
cholangitis accompanying severe inflammation, fibrosis, and epithelial injuries and this 
characteristic feature is known as fibrosclerosing cholangitis. Little is known about the etiology and 
pathogenesis of BA, but infections by viruses such as Reoviridae (reovirus and rotavirus) having a 
double-stranded RNA (dsRNA) have been implicated, though conflicting results also have been 
reported [1-8]. Our recent study has demonstrated that biliary epithelial cells (BECs) possess an 
innate immune system consisting of Toll-like receptors (TLR), especially TLR3 which is an innate 
immune-recognition receptor recognizing dsRNA including dsRNA viruses as pathogen-associated 
molecular patterns (PAMPs) [9, 10]. Furthermore, the biliary innate immune response to artificial 
dsRNA was also shown to be associated with the induction of biliary apoptosis via the tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) and, differing from the innate immune 
response to TLR4 ligand (LPS), lack of subsequent tolerance to dsRNA using cultured human biliary 
epithelial cells [9-11]. 
 Interleukin (IL)-32 is a recently described cytokine produced by T lymphocytes, natural 
killer (NK) cells, monocytes and some epithelial cells [12, 13]. Primarily, IL-32 was discovered in 
the synovial fluid of patients with rheumatoid arthritis and first reported as a transcript in IL-2 
activated NK and T cells [14, 15]. There are six isoforms (α, β, γ, δ, ε, and ξ) caused by alternative 
mRNA splicing, resulting in proteins with a molecular weight ranging from 14.9 to 26.7 kD. IL-32α 
is the most abundant transcript. IL-32 exhibits several properties typical of proinflammatory 
cytokines [16]. For example, it stimulates the secretion of proinflammatory cytokines and 
chemokines such as IL-1α, TNF-α, IL-6, IL-8 and VEGF through the activation of nuclear factor-κB 
(NF-κB) and p38 mitogen-activated protein kinases (MAPKs) [15, 17, 18]. In contrast, the 
production of IL-32 is induced or enhanced by the presence of proinflammatory cytokines including 
IL-1β, IFN-γ, and TNF-α via the activation of caspase 1 [17, 19, 20]. IL-32 has been implicated in 
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inflammatory disorders such as rheumatoid arthritis, inflammatory bowel diseases, chronic 
obstructive pulmonary diseases, atopic dermatitis, and allergic rhinitis [14, 19-22].  
 Although human hepatocytes and hepatoma cells express IL-32 in HCV-associated chronic 
hepatitis and the expression is regulated by proinflammatory stimuli [23], the pathophysiological 
role of IL-32 in innate immune-related biliary diseases including BA remains unclear. We therefore 
investigated the IL-32 expression in the inflamed bile ducts of BA patients and the effect of innate 
immune stimulation by ligands of TLR3 and cytokines on IL-32 expression in cultured human BECs. 
Our results provide evidence that biliary epithelial cells are sufficient sources of IL-32 for the biliary 
inflammation at sites of BA and IL-32 may therefore play a role in the pathophysiology of BA. 
 
 
MATERIALS AND METHODS 
 
Patients and tissue preparations 
 A total of 21 patients with BA (surgical specimens; average age 1.7 months; range of age 
0.7-12 months; male/female=9/12) and age-matched control patients consisting of one neonatal 
hepatitis (giant cell hepatitis; wedge biopsy; 3 months; male) and 6 non-hepatobiliary diseases 
(congenital heart anomalies; autopsied specimens; average age 2.5 months; male/female=3/3) were 
examined. Resected common bile ducts and wedge liver biopsy specimens obtained at Kasai 
procedure from the patients with BA were used. These specimens had been fixed in 10% 
neutral-buffered formalin and embedded in paraffin; 4µm-thick sections were prepared for histologic 
observation and immunohistochemistry.  
Immunohistochemistry and immunocytochemistry 
For the immunocytochemistry using cultured BECs, formalin-fixed, paraffin-embedded 
sections of cell blocks were prepared according to the protocol reported by Mayall, et al [24]. The 
deparaffinized and rehydrated sections were heated in 10mM citrate buffer for 20min in a 
microwave oven. Following the blocking of endogenous peroxidase, these sections were incubated at 
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4ºC overnight with antibody against the C-terminus of IL-32 (rabbit polyclonal IgG, 1µg/ml, 
Lifespan, Seattle, WA, USA), TLR3 (rabbit polyclonal IgG, 1µg/ml, Santa Cruz, Santa Cruz, CA, 
USA), and caspase 1 (rabbit monoclonal IgG, diluted 1:1,000, Abcam, Tokyo, Japan) and then at 
room temperature for 1h with anti-rabbit immunoglobulins conjugated to a peroxidase-labeled 
dextran polymer (Simple staining kit, Nichirei, Tokyo, Japan). After a benzidine reaction, sections 
were lightly counterstained with hematoxylin. As a negative control, normal rabbit IgG was used as 
the primary antibody: no staining was obtained.  
For the semi-quantitative evaluation of the immunohistochemistry, intrahepatic bile ducts 
and extrahepatic common bile ducts were chosen in each section for assessment and IL-32 
immunoreactivity in these bile ducts was semiquantitatively graded as follows: score 0, absence of 
expression; score 1, low constitutive expression; score 2, intermediate expression; score 3, high 
expression.  
 In addition, simultaneous detection of IL-32 and cytokeratin (CK)19 was done using 
double immunohistochemical staining. After IL-32 immunostaining, CK19 antibody (mouse 
monoclonal IgG1kappa, 0.45µg/ml, Dako Japan, Tokyo, Japan) was applied overnight at 4oC, 
followed by immunoglobulins conjugated to alkaline phosphatase labeled-dextran polymer 
(Nichirei). Color development of IL-32 and CK19 was achieved with diaminobenzidine (brown) and 
Vector blue (Vector Lab, Burlingame, CA, USA.), respectively.   
 
Cultured human BECs and stimulation with PAMPs and proinflammatory cytokines 
 A cultured cell line of human intrahepatic BECs was established from the explant liver of a 
24-year-old male with BA who had already received Kasai procedure during the newborn period, 
and cultured as previously reported [25] The cultured BECs were incubated with a culture medium 
composed of D-MEM/F-12 (Invitrogen, Tokyo, Japan), 5% newborn calf serum (Invitrogen), 
0.18mM adenine (Sigma, Saint Louis, MO, USA), hydrocortisone (0.4µg/ml), cholera toxin 
(10ng/ml), tri-iodo-thyronine (1.3µg/l), ITS+ (Becton Dickinson, Franklin Lakes, NJ, USA), 25mM 
sodium bicarbonate (Sigma), 1% antibiotics antimycotic, human epidermal growth factor(20ng/ml) 
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(Invitrogen), and human hepatocyte growth factor(10ng/ml) (Invitrogen). The cells were grown as 
monolayers in a humidified incubator with 5% CO2 at 37
o
C. More than 95% of the cells were 
confirmed to be biliary epithelial cells by the expression of a biliary-type cytokeratin (CK19). The 
cultured BECs were used between passages 4 and 9. Informed consent for human research was 
obtained from the patient prior to surgery. This study was approved by the Kanazawa University 
Ethics Committee. Moreover, as control cultured cells, a commercially available cell line derived 
from human hepatocellular carcinoma, HepG2, was obtained from Health Science Research 
Resources Bank (Osaka, Japan).  
These cultured cells were stimulated with a TLR3 ligand, polyinosinic-polycytidylic acid 
(poly(I:C), a synthetic analogue of viral dsRNA, 25µg/ml, Invivogen, San Diego, CA, USA) and 
recombinant cytokines (IL-1β, IFN-γ, TNF-α, TGF-β1, and IL-10, l,000U/ml, PeproTech, London, 
and IL-32, 1,000U/ml, R&D system, Minneapolis, MN, USA) for 3 hrs (molecular analysis) and 48 
hrs (protein analysis by immunocytochemistry and Western blotting analysis). 
 
Isolation of RNA, reverse transcription-polymerase chain reaction (RT-PCR), and real-time PCR  
 For the evaluation of mRNA of IL-32, caspase 1, TLR3, IL-1β, and IL-6, in cultured BECs, 
isolation of RNA from BECs and reverse transcription were performed using the RNeasy Total RNA 
System (Qiagen, Hilden, Germany) and ReverTra Ace (Toyobo, Osaka, Japan). First, to examine the 
presence of target molecules and the validity of the newly designed primers, conventional PCR was 
performed. Specific primers for IL-32, caspase 1, TLR3, and glyceraldehyde 3 phosphate 
dehydrogenase (GAPDH, positive control) were designed: IL-32 forward, 
5’-AGCTGGAGGACGACTTCAAA-3’, and reverse, 5’-TTGAGGATTGGGGTTCAGAG-3’ 
(predicted size, 258bp); TLR3 forward, 5’-CCATTCCAGCCTCTTCGTAA-3’, and reverse, 
5’-GGATGTTGGTATGGGTCTCG-3’ (predicted size, 505bp); caspase 1 forward, 
5’-CCACAATGGGCTCTGTTTTT-3’, and reverse, 5’-CATCTGGCTGCTCAAATGAA-3’ 
(predicted size, 117); IL-1β, forward, 5'-CCAGGGACAGGATATGGAGCA-3' and reverse, 
5'-TTCAACACGCAGGACAGGTACAG-3' (predicted size, 129bp); IL-6, forward, 
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5'-AGTGAGGAACAAGCCAGAGC-3' and reverse, 5'-AAGCTGCGCAGAATGAGAT-3' 
(predicted size, 189bp); GAPDH, forward, 5’-GGCCTCCAAGGAGTAAGACC-3’, and reverse, 
5’-AGGGGTCTACATGGCAACTG-3’ (predicted size, 147bp). The reaction profile consisted of 
initial denaturation at 94ºC for 3min followed by 25-40 cycles with 30sec of denaturation at 94ºC, 
30sec of annealing of primers at 55ºC, and a 60sec extension at 72ºC. Next, to carry out relative 
quantification, real-time quantitative PCR was performed according to a standard protocol using the 
Brilliant II SYBR Green QPCR Reagents and Mx300P QPCR system (Stratagene Japan, Tokyo, 
Japan). Relative gene expression was calculated using the comparative cycle threshold method and 
adjusted based on the expression of house-keeping gene (GAPDH). Results were obtained from 
three independent experiments and shown as relative mRNA expression compared with the level 
without any treatments. Negative controls were obtained by replacing the reverse transcriptase or 
cDNA samples with RNase and DNase free water. 
 
Western blotting 
Cell lysates of poly(I:C)-stimulated or unstimulated cultured cell lines (10µg protein/lane) and 
the culture medium were subjected to SDS-PAGE. Recombinant IL32 protein (0.1µg, R&D) was 
used as a positive control. Separated proteins were transferred to a nitrocellulose membrane; the 
membrane was blocked in 5% bovine serum albumin, and then probed for 1h with a primary antibody 
against human IL-32 (0.1µg/ml). After a wash, the membrane was incubated for 1h with a Simple 
Staining Kit, and visualized with the benzidine reaction. The density of bands was quantitatively 
evaluated by using NIH images. 
 
Statistical analysis 
 Data were analyzed using the paired t-test or Welch’s t-test; p<0.05 was considered 
statistically significant.  
 
 


































































Expression of IL-32, caspase 1, and TLR3 in extrahepatic bile ducts of BA 
Immunohistochemistry revealed the expression of IL-32 in BECs, infiltrating inflammatory 
cells, and endothelial cells at various intensities. In particular, damaged common bile ducts showing 
cholangitis in BA strongly expressed IL-32, accompanying many IL-32-positive inflammatory cells 
and vessels (Fig.1A, 1B, 1C). As shown in Fig.1F, the double immunohistochemistry highlighted 
that CK19-postive bile ducts clearly expressed IL-32. However, non-damaged biliary epithelium 
found at the margin of resected common bile ducts did not express IL-32 (Fig.1G and 1H). In wedge 
liver biopsies, hepatocytes were also positive for IL-32 in addition to small bile ducts (interlobular 
bile ducts), but the intensity was lower than that in damaged common bile ducts (Fig.1I and 1J). 
Moreover, congestive bile in intrahepatic bile ducts was also strongly positive for IL-32 (Fig.1J). In 
contrast, BECs in common bile ducts and intrahepatic bile ducts of age-matched controls, only 
weakly expressed or lacked IL-32 (Fig2A and 2D). The semi-quantitative analysis for 
immunoreaction confirmed the expression of IL-32 in damaged common bile ducts of BA was 
significantly upregulated, compared with those in non-damaged/normal bile ducts of BA and 
age-matched controls (Fig.3). Caspase 1 and TLR3 were constantly expressed in BECs of 
extrahepatic bile ducts, in both the BA and control patients (Fig.2B and 2C).  
 
Induction of IL-32 expression by PAMPs and cytokines in cultured BECs 
To examine the presence of target molecules and the validity of the newly designed primers, 
RT-PCR at 40 cycles was performed and an amplification of all molecules could be detected as a 
single band from cultured BECs at the expected size. Moreover, the BECs constantly expressed the 
mRNA of TLR3 and caspase 1, which is necessary for the recognition of poly(I:C) and the 
production of functional IL-32 protein, respectively. The real-time PCR analysis revealed that TLR3 
ligand, poly(I:C) and proinflammatory cytokines (IL-1β, IFN-γ, and TNF-α), but not regulatory 
cytokines (TGF-β1 and IL-10), enhanced the mRNA expression of IL-32, with the increases being 
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statistically significant (Fig.4A). In contrast, the stimulation with IL-32 did not significantly 
upregulated the expression of BEC-producing cytokines (IL-1β, IL-6, and IL-32), TLR3, and 
caspase 1 in cultured BECs (Fig.4B). Although the control cell line, HepG2, also expressed IL-32 
mRNA, the upregulation of IL-32 was not significant by the stimulation with poly(I:C) or IL-32 
(Fig.4C).  
 
Detection of intracytoplasmic and secreted IL-32protein 
 To investigate the secretion of the IL-32 protein, Western blotting was performed using the 
cell lysate and culture medium of BECs. IL-32 was detected in the medium as well as lysate from 
the poly(I:C)-stimulated BECs (Fig.5A). Semi-quantitative analysis using NIH image analysis 
revealed that the density of bands was upregulated in cell lysate and culture medium by the 
stimulation with poly(I:C) (Fig.5A). Moreover, immunocytochemistry also demonstrated that IL-32 







 BA is initially characterized by periductal inflammation and fibrosis, and the obstruction 
of common bile ducts, known as fibrosclerosing cholangitis. Recruitment of inflammatory cells 
results in the release of other proinflammatory cytokines and chemokines, sustaining the cholangitis 
associated with the biliary innate immune response and promoting the chronic cholangitis associated 
with the subsequent acquired immune response in a later phase [26]. IL-32 is a recently described 
cytokine that is a strong inducer of pro-inflammatory cytokines and whose expression is markedly 
increased in several inflammatory disorders including RA and IBD and correlated with the severity 
of these diseases [14, 19]. In the present study, human BECs were demonstrated to be the local 
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source of IL-32. Immunohistochemical analysis showed a cytoplasmic distribution of IL-32 in BECs 
of the damaged common bile ducts in the cases of BA, though BECs of common bile ducts in 
age-matched controls were negative or only weakly positive for IL-32, suggesting that IL-32 is 
closely associated with the histogenesis of periductal inflammation in BA. However, the event of 
IL-32 production in BECs is not be specific for only BA. In facts, we confirmed the expression of 
IL-32 in bile ducts of adult biliary diseases such as primary biliary cirrhosis, but its intensity was 
lower than those in the damaged common bile ducts of BA. Therefore, we speculated that the 
induction of IL-32 by unique factors such as viral infections in BA was stronger than those in other 
biliary diseases. Inflammasomes are multi-protein cytoplasmic complexes that mediate the activation 
of inflammatory caspase-1. For example, caspase-1 cleaves pro-IL-1β to the active form IL-1β. In 
this manner, caspase-1 controls the maturation of some of the pro-inflammatory cytokines and IL-32 
also depended on the activation of caspase 1 [17, 20]. Therefore, the presence of caspase 1 is 
necessary for the functional expression of IL-32 in BECs. In the present study, BECs constantly 
expressed caspase 1 in vitro and in vivo, suggesting the expression of a functional IL-32 in BECs.  
 Recent studies have focused on the role of innate immunity associated with Reoviridae 
(reovirus and rotavirus) in the pathogenesis of BA. Reoviridae having a dsRNA genome, in 
particular, are characterized by epithelial tropism [1, 3, 4, 9, 10, 27, 28]. The initial sensing of innate 
immunity is mediated by the recognition of PAMPs through TLRs. IL-32 also appears to play an 
important role in host defense against invading micro-organisms [23, 29, 30]. That is, IL-32 is 
described as a pro-inflammatory cytokine that enhances host immunity against various microbial 
pathogens. The present study revealed that stimulation with poly(I:C), a mimic of Reoviridae, 
enhanced the expression of IL-32 in cultured BECs, suggesting that the biliary innate immune 
response directly induces the production of IL-32 in BECs. A control cell line used in this study, 
HepG2, also expressed IL-32 mRNA, but the upregulation of IL-32 was not significant by the 
stimulation with poly(I:C). It has already been reported that IL-32 expression is induced in 
peripheral blood mononuclear cells and monocytes by Mycobacterium tuberculosis [31], but to our 
knowledge this is the first description concerning the production of IL-32 in epithelial cells such as 
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BECs via an innate immune response.  
 IL-1β, IFN-γ, and TNF-α were reported to be inducers of IL-32 expression [16, 19]. 
However, the regulatory mechanism of these pro-inflammatory cytokines remains unclear. In this 
study, we found that all these pro-inflammatory cytokines are potent stimulators of IL-32 expression 
in cultured BECs. In contrast, the aforementioned results suggest that the secretion of IL-32 could 
stimulate periductal inflammatory and/or immune cells to secrete proinflammatory cytokines and 
contributes to the deterioration of periductal inflammation. Because these inflammatory cytokines 
and an innate immunity play important roles in the immune-mediated histogenesis of BA, the 
inflammatory responses and innate immune response in the affected bile ducts of BA patients may 
be amplified by constant IL-32-induced secretion of proinflammatory cytokines from BECs and 
periductal inflammatory cells, suggesting that IL-32 plays a central role in the inflammatory 
responses involved in the pathogenesis of BA. However, IL-32 itself could not upregulate the 
expression of inflammatory cytokines (IL-1β, IL-6, and IL-32), TLR3, and caspase 1 in cultured 
BECs, suggesting that IL-32 produced by BECs was unlikely involved in direct reciprocal signaling 
resulting in upregulation of inflammatory cytokines and of susceptibility to virus in BECs. 
 In this study, we demonstrated that stimulation with poly(I:C) induced the transcription of 
IL-32 mRNA in BECs and also confirmed the presence of the protein in the culture medium as well 
as cell lysate. Moreover, immunohistochemistry also revealed that a condensed bile in intrahepatic 
small bile ducts was positive for IL-32. These findings suggest the secretion of IL-32 from 
IL-32-expressing BECs. Therefore, IL-32 is speculated to be extracellularly secreted in periductal 
tissue fluids and into bile in BA. As mentioned above, the secreted IL-32 induces the production of 
proinflammatory cytokines in inflammatory and/or immune cells, resulting in a marked 
amplification of inflammatory cytokine milieu, and these responses may contribute to the 
aggravation of BA. Moreover, it was recently suggested that IL-32 acts as a cytoplasmic protein: 
IL-32 was expressed at high levels in human epidermal keratinocytes after stimulation with IFN-γ 
and TNF-α, but was not secreted by keratinocytes [21]. Moreover, it was also shown that the 
upregulation of cytoplasmic IL-32 expression induces apoptosis [21, 32]. In IBD, the apoptosis of 
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damaged colonic cells by accumulated intracellular IL-32 can be considered a host defense 
mechanism against invading microorganisms, by which damaged epithelial cells are eliminated 
efficiently along with invading microorganisms and further invasions of microorganisms can be 
blocked [19, 33]. In BA, our previous study found that biliary apoptosis was enhanced in the 
damaged common bile ducts and closely associated with bile duct loss in BA, which was caused by 
the production of an apoptosis-inducer, TRAIL, in BECs via the biliary innate immune response to a 
TLR3 ligand, poly(I:C) [10]. However, this TRAIL-mediated biliary apoptosis is only partially 
involved in the poly(I:C)-induced mechanism and other possible mechanisms also could exist [10]. 
Therefore, the IL-32-mediated mechanism is also likely in the poly(I:C)-induced biliary apoptosis 
and might be associated with the enhanced biliary apoptosis in the damaged common bile ducts of 
BA. 
 In conclusion, we have demonstrated that IL-32 expression is enhanced in the damaged 
common bile ducts of BA patients. Expression of IL-32 in BECs was induced by the innate immune 
response to dsRNA (poly(I:C)) and proinflammatory cytokines (IL-1β, IFN-γ, and TNF-α). This 
study identified IL-32 as an important inflammatory cytokine involved in the cholangitis of BA. So 
far, anti-IL32 treatment has been studied in a few diseas s such as rheumatoid arthritis [34, 35]. The 
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Fig.1  Histology and immunohistochemistry for IL-32, TLR3, and caspase 1 in biliary atresia (BA). 
A and B: Transverse sections of biliary remnants. Damaged extrahepatic bile ducts 
inconsistently line by desquamated columnar epithelium and surrounding fibroplasia with an 
inflammatory cell infiltrate. B is a higher magnification of A. H&E staining. Original 
magnification, A, x100 and B, x400. C, D, and E: Immunohistochemistry for IL-32 (C), TLR3 
(D), and caspase 1 (E). The strong expression of IL-32, TLR3, and caspase 1 was found in 
biliary epithelial cells (arrows) of damage bile ducts. Original magnification, x400. F: Double 
immunohistochemistry for CK19 and IL-32 highlighted the CK19-postive bile ducts (blue) 
clearly expressed IL-32 (brown) (arrows). Original magnification, x400. G and H: 
Immunohistochemistry for IL-32. Undamaged extrahepatic bile duct located at the resected 
margin in BA. IL-32-positive neovascular structures (arrowhead) were found, but undamaged 
biliary epithelium lacked IL-32 expression (arrows). H is higher magnification of G. Original 
magnification, G, x200 and H, x400. I and J: Immunohistochemistry for IL-32 using wedge 
liver specimens of BA. Interlobular bile ducts (arrows in I) and hepatocytes (HC in I) 
expressed IL-32. Moreover, condensed bile in dilated bile ducts was also strongly positive for 
IL-32 (arrows in J). J is a higher magnification of I. Original magnification, E, x200 and F, 
x400.  
 
Fig.2  Immunohistochemistry for IL-32 (A and D), TLR3 (B), and caspase 1 (C) in age-matched 
controls. A, B, and C: Biliary epithelial cells in common bile ducts of non-hepatobiliary 
diseases (congenital heart anomalies) expressed TLR3 (B) and caspase 1 (C), but lack or 
faintly expressed IL-32 (A). was faint or negative. Original magnification, x200. D: 
Interlobular bile duct in neonatal hepatitis was negative for IL-32 (arrow). Original 
magnification, x400. 
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Fig.3  Semi-quantitative analysis of immunohistochemistry for IL-32. The expression of IL-32 in 
damaged common bile ducts (CBD) of biliary atresia (BA) was significantly upregulated, 
compared with those of non-damaged CBD and interlobular bile ducts (ILBD) in BA, and of 
CBD and ILBD in age-matched controls. *<0.05. 
 
Fig.4 A: Induction of IL-32 expression by TLR3 ligand (poly I:C) and cytokines in cultured biliary 
epithelial cells (BECs). Quantitative analysis using real-time PCR revealed that a TLR3 
ligand, poly(I:C), and proinflammatory cytokines (IL-1β, IFN-γ, and TNF-α), but not 
regulatory cytokines (TGF-β1 and IL-10), significantly upregulated the mRNA expression of 
IL-32. B: Detection of BEC-producing cytokines (IL-1β, IL-6, and IL-32), TLR3, and caspase 
1 in cultured BECs. The stimulation with IL-32 did not significantly upregulated the 
expression of any cytokines, TLR3, or caspase 1. C: Detection of IL-32 in a control cell line, 
HepG2. Induction of IL-32 expression was not found by the stimulation with poly(I:C) or 
IL-32. Results were obtained from three independent experiments and shown as relative 
mRNA expression compared with the level without any treatments (Non). Bars indicate the 
mean±S.E.M. *<0.05. 
 
Fig.5 Detection of intracytoplasmic and secreted IL-32 protein in cultured biliary epithelial cells 
(BECs). A: Western blotting revealed that the culture medium as well as cell lysate of 
poly(I:C)-treated cultured cells contained IL-32 protein, but the level was faint in untreated 
cells (Non). As a positive control, recombinant IL-32 (rIL32, 0.1µg) was used. 
Semi-quantitative analysis using NIH image analysis confirmed that the density of bands was 
upregulated in cell lysate and culture medium by the stimulation with poly(I:C). B: 
Immunocytochemistry also demonstrated that IL-32 was strongly expressed in the 
poly(I:C)-stimulated BECs, compared with the unstimulated BECs (Non). Original 
magnification, x400. 
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